Krensavage Asset Management Remains Opposed to Sun Pharma's Predatory Bid for Taro Pharma

1/30/24 7:07:05 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $TARO alert in real time by email

Krensavage Asset Management today sent the following message to a special committee evaluating Sun Pharmaceutical Industries Ltd.'s bid for Taro Pharmaceutical Industries Ltd.

Dear Linda,

As the largest minority shareholder1 of Taro Pharmaceutical Industries Ltd. (NYSE:TARO), Krensavage Asset Management LLC remains opposed to Sun Pharmaceutical Industries Ltd.'s inadequate bid to take Taro private.

Get the next $TARO alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$TARO

Date	Price Target	Rating	Analyst
1/18/2024	$43.00	Buy → Neutral	H.C. Wainwright
1/31/2022	$75.00 → $73.00	Buy	HC Wainwright & Co.
1/18/2022	$82.00 → $75.00	Buy	HC Wainwright & Co.
7/28/2021	$80.00 → $82.00	Buy	HC Wainwright & Co.

More analyst ratings

$TARO
Press Releases

Fastest customizable press release news feed in the world

Sun Pharma Completes Taro Merger
Combined entity is better positioned to compete in increasingly competitive generics industry MUMBAI, India and PRINCETON, N.J., June 24, 2024 /PRNewswire/ -- Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715 (together with its subsidiaries and/or associated companies, "Sun Pharma")) today announced the successful completion of the merger of Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro") with its subsidiary. As part of this merger, Sun Pharma acquired all outstanding ordinary shares of Taro other than the shares already held by Sun Pharma or its affiliates. As a result of the merger, Taro is now a private company and wholly-own
6/24/24 7:47:00 AM ET
$TARO
Biotechnology: Pharmaceutical Preparations
Health Care
Taro Shareholders Approve Merger with Sun Pharma
MUMBAI, India and NEW YORK, May 23, 2024 /PRNewswire/ -- Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associates referred as "Sun Pharma") and Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company") today announced that the merger agreement between Taro and Sun Pharma was approved by the affirmative vote of Taro shareholders (including a vote of the majority of shares held by Taro shareholders unaffiliated with Sun Pharma) at an Extraordinary General Meeting and an Ordinary Class Meeting on May 22, 2024. The details of the merger agreement were announced on January 17, 2024.
5/23/24 7:50:00 AM ET
$TARO
Biotechnology: Pharmaceutical Preparations
Health Care
Taro Provides Results for Year Ended March 31, 2024
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company") today provided unaudited financial results for the quarter and year ended March 31, 2024. Quarter ended March 31, 2024 Highlights ─ compared to March 31, 2023 Net sales of $164.9 million increased $18.4 million, or 12.5%, principally due to new launches and gross-to-net ("GTN") adjustments. Excluding the impact of GTN adjustments, sales growth was high single digits. Gross profit of $87.4 million (53.0% of net sales) compared to $75.7 million (51.6% of net sales). Research and development (R&D) expenses of $20.5 million increased $4.2 million. Selling, marketing, general and administrative expenses (SG&A
5/20/24 5:00:00 PM ET
$TARO
Biotechnology: Pharmaceutical Preparations
Health Care

$TARO
Financials

Live finance-specific insights

Taro to Release Third Quarter Results on January 25, 2024
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for the third quarter ended December 31, 2023, after the close of market on Thursday, January 25, 2024. The release will be accessible on Taro's website at www.taro.com. About Taro Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. For further information on Taro Pharmaceutical Industries Ltd., please visit the Company's website at www.taro.com. View source version on businesswir
1/19/24 4:15:00 PM ET
$TARO
Biotechnology: Pharmaceutical Preparations
Health Care
Taro to Release Second Quarter Results on October 26, 2023
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for the second quarter ended September 30, 2023, after the close of market on Thursday, October 26, 2023. The release will be accessible on Taro's website at www.taro.com. About Taro Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. For further information on Taro Pharmaceutical Industries Ltd., please visit the Company's website at www.taro.com. View source version on businessw
10/19/23 4:30:00 PM ET
$TARO
Biotechnology: Pharmaceutical Preparations
Health Care
Taro to Release First Quarter Results on July 26, 2023
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for the first quarter ended June 30, 2023, after the close of market on Wednesday, July 26, 2023. The release will be accessible on Taro's website at www.taro.com. About Taro Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. For further information on Taro Pharmaceutical Industries Ltd., please visit the Company's website at www.taro.com. View source version on businesswire.com: h
7/19/23 4:00:00 PM ET
$TARO
Biotechnology: Pharmaceutical Preparations
Health Care

Krensavage Asset Management Remains Opposed to Sun Pharma's Predatory Bid for Taro Pharma

Chat with this insight

Recent Analyst Ratings for
$TARO

$TARO
Press Releases

Fastest customizable press release news feed in the world

Sun Pharma Completes Taro Merger

Taro Shareholders Approve Merger with Sun Pharma

Taro Provides Results for Year Ended March 31, 2024

$TARO
Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13D/A filed by Taro Pharmaceutical Industries Ltd.

SEC Form SC 13D/A filed by Taro Pharmaceutical Industries Ltd. (Amendment)

SEC Form SC 13D/A filed by Taro Pharmaceutical Industries Ltd. (Amendment)

$TARO
Leadership Updates

Live Leadership Updates

Taro Appoints New Chief Financial Officer

Taro Announces Resignation of Chief Financial Officer

$TARO
Market Insights

Live Market Insights

Sun Pharmaceutical And Taro Pharmaceutical Industries' Merger Agreement Was Approved By The Affirmative Vote Of Taro Shareholders

Taro Pharmaceutical Indus Q4 Adj EPS $0.43 Beats $0.31 Estimate, Sales $164.941M Beat $156.062M Estimate